Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2008 1
2010 1
2011 2
2012 3
2013 1
2014 1
2018 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study.
Boulton C, Meiser K, David OJ, Schmouder R. Boulton C, et al. J Clin Pharmacol. 2012 Dec;52(12):1879-90. doi: 10.1177/0091270011427908. Epub 2011 Dec 15. J Clin Pharmacol. 2012. PMID: 22174429 Clinical Trial.
A reduction in peripheral lymphocyte count is an expected consequence of the fingolimod mechanism of S1PR modulation. The authors investigated if this pharmacodynamic effect impacts humoral and cellular immunogenicity. In this double-blind, parallel-group, 4- …
A reduction in peripheral lymphocyte count is an expected consequence of the fingolimod mechanism of S1PR modulation. The authors inv …
Clinical pharmacokinetics of fingolimod.
David OJ, Kovarik JM, Schmouder RL. David OJ, et al. Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22149256 Review.
Fingolimod and fingolimod phosphate have a half-life of 6-9 days, and steady-state pharmacokinetics are reached after 1-2 months of daily dosing. ...Population pharmacokinetic evaluations indicate that CYP3A inhibitors and CYP3A inducers have no eff …
Fingolimod and fingolimod phosphate have a half-life of 6-9 days, and steady-state pharmacokinetics are reached …
The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
Kovarik JM, Lu M, Riviere GJ, Barbet I, Maton S, Goldwater DR, Schmouder RL. Kovarik JM, et al. Eur J Clin Pharmacol. 2008 May;64(5):457-63. doi: 10.1007/s00228-007-0448-4. Epub 2008 Jan 15. Eur J Clin Pharmacol. 2008. PMID: 18196225 Clinical Trial.
OBJECTIVE: The sphingosine-1-phosphate receptor modulator fingolimod (FTY720) is known to elicit a negative chronotropic effect at treatment initiation that attenuates over time with continued dosing. The authors determined the effect of combining a single do …
OBJECTIVE: The sphingosine-1-phosphate receptor modulator fingolimod (FTY720) is known to elicit a negative chronotropic effect …
Pharmacokinetic Interaction Between Fingolimod and Carbamazepine in Healthy Subjects.
David OJ, Behrje R, Pal P, Hara H, Lates CD, Schmouder R. David OJ, et al. Clin Pharmacol Drug Dev. 2018 Aug;7(6):575-586. doi: 10.1002/cpdd.459. Epub 2018 Apr 25. Clin Pharmacol Drug Dev. 2018. PMID: 29694732 Free PMC article.
This open-label, single-sequence study in healthy subjects investigated the effects of steady-state carbamazepine on the pharmacokinetic (PK) profile of a single 2-mg dose of fingolimod. ...The PK analysis included 23 of 26 of the enrolled subjects (88 …
This open-label, single-sequence study in healthy subjects investigated the effects of steady-state carbamazepine on th …
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.
Francis G, Kappos L, O'Connor P, Collins W, Tang D, Mercier F, Cohen JA. Francis G, et al. Mult Scler. 2014 Apr;20(4):471-80. doi: 10.1177/1352458513500551. Epub 2013 Aug 15. Mult Scler. 2014. PMID: 23950550 Clinical Trial.
BACKGROUND: Reduction in peripheral blood lymphocytes is an expected pharmacodynamic outcome of fingolimod therapy. OBJECTIVE: The objective of this article is to evaluate lymphocyte dynamics during and after fingolimod therapy and assess the relationship bet …
BACKGROUND: Reduction in peripheral blood lymphocytes is an expected pharmacodynamic outcome of fingolimod therapy. OBJECTIVE: …
FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
Kovarik JM, Schmouder RL, Barilla D, Büche M, Rouilly M, Berthier S, Wang Y, Van Saders C, Mayer T, Gottlieb AB. Kovarik JM, et al. Ann Pharmacother. 2004 Jul-Aug;38(7-8):1153-8. doi: 10.1345/aph.1E035. Epub 2004 May 11. Ann Pharmacother. 2004. PMID: 15138297 Clinical Trial.
The single-dose pharmacokinetics of FTY720 and the steady-state pharmacokinetics of cyclosporine were characterized when given alone and during coadministration. ...CONCLUSIONS: The pharmacokinetics of single-dose FTY720 and steady-state cyclosporine w …
The single-dose pharmacokinetics of FTY720 and the steady-state pharmacokinetics of cyclosporine were characterized when given …
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
David OJ, Ocwieja M, Meiser K, Emotte C, Jakab A, Wemer J, den Daas I, Schmouder R. David OJ, et al. Int J Clin Pharmacol Ther. 2012 Aug;50(8):540-4. doi: 10.5414/CP201675. Int J Clin Pharmacol Ther. 2012. PMID: 22735460
To assess whether the efficacy of a combined oral contraceptive (OC) could be compromised during fingolimod therapy, a steady-state, drug-drug interaction study of fingolimod with ethinylestradiol/levonorgestrel was performed in healthy female voluntee …
To assess whether the efficacy of a combined oral contraceptive (OC) could be compromised during fingolimod therapy, a steady- …
Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720.
Morris MA, Gibb DR, Picard F, Brinkmann V, Straume M, Ley K. Morris MA, et al. Eur J Immunol. 2005 Dec;35(12):3570-80. doi: 10.1002/eji.200526218. Eur J Immunol. 2005. PMID: 16285007 Free article.
Following a transient increase in peripheral lymph nodes and Peyer's patches, lymphocyte recirculation reaches a new steady state. Other lymphoid organs show transient changes in lymphocyte composition with various patterns. At 21 days of FTY720 treatment, total bod …
Following a transient increase in peripheral lymph nodes and Peyer's patches, lymphocyte recirculation reaches a new steady state …
Differential responses of human microglia and blood-derived myeloid cells to FTY720.
Durafourt BA, Lambert C, Johnson TA, Blain M, Bar-Or A, Antel JP. Durafourt BA, et al. J Neuroimmunol. 2011 Jan;230(1-2):10-6. doi: 10.1016/j.jneuroim.2010.08.006. Epub 2010 Sep 9. J Neuroimmunol. 2011. PMID: 20826007
Despite similar receptor expression patterns, the distinct myeloid cell populations present in the human CNS, under steady-state or inflammatory conditions, exhibit differential responses to FTY720....
Despite similar receptor expression patterns, the distinct myeloid cell populations present in the human CNS, under steady-state …